“…The clinical applications for AMPs will possibly rely on overcoming the poor stability of natural AMPs and their toxic effects on the patient, e.g., hemolysis; therefore, developing synthetic and long-lasting AMP derivatives has been considered a powerful strategy for the future pharmacology of AMPs [24,25]. For example, antimicrobial peptide-polymer conjugates [24,26] not only preserve excellent antimicrobial activity but also show reduced toxicity, offering more functionalities as those represented by biomedical materials such as hydrogels [27], polymeric materials with applications in wound dressings [28], orthopedic implant coatings [29], antibiofilm materials [30,31], engineered tissues, etc. [32][33][34][35][36].…”